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Adenovirus-mediated combination gene therapies have shown
promising results in vaccination or treating malignant and ge-
netic diseases. Nevertheless, an efficient system for the rapid
assembly and incorporation of therapeutic genes into high-ca-
pacity adenoviral vectors (HCAdVs) is still missing. In this
study, we developed the iMATCH (integrated modular assem-
bly for therapeutic combination HCAdVs) platform, which en-
ables the generation and production of HCAdVs encoding
therapeutic combinations in high quantity and purity within
3 weeks. Our modular cloning system facilitates the efficient
combination of up to four expression cassettes and the rapid
integration into HCAdV genomes with defined sizes. Helper
viruses (HVs) and purification protocols were optimized to
produce HCAdVs with distinct capsid modifications and un-
precedented purity (0.1 ppm HVs). The constitution of
HCAdVs, with adapters for targeting and a shield of trimerized
single-chain variable fragment (scFv) for reduced liver clear-
ance, mediated cell- and organ-specific targeting of HCAdVs.
As proof of concept, we show that a single HCAdV encoding
an anti PD-1 antibody, interleukin (IL)-12, and IL-2
produced all proteins, and it led to tumor regression and pro-
longed survival in tumor models, comparable to a mixture of
single payload HCAdVs in vitro and in vivo. Therefore, the iM-
ATCH system provides a versatile platform for the generation
of high-capacity gene therapy vectors with a high potential for
clinical development.
INTRODUCTION
Gene therapy comprises viral, bacterial, and cellular vectors with
cellular therapies, also including stem cell therapies.1,2 Viral gene
therapy has come a long way since the early 1990s, when human ad-
enoviruses (HAdVs) were first vectorized and applied in attempts to
treat monogenic cystic fibrosis lung disease.3–7 Today, viral gene ther-
apy with a variety of viruses is used in oncology, vaccination, and
many other disciplines in clinical science.8–11 Gene therapy vectors
have been used preclinically for host genome editing and clinically
for the expression of intracellular proteins, surface receptor presenta-
tion, and/or the secretion of therapeutics.12–15 Recently, multiple gene
delivery vectors have been developed in the expanding field of cancer
immunotherapy.16 Cancer immunotherapy approaches modulate the
activity of immune cells against cancer cells in various ways, e.g., by
rendering the immunosuppressive state of the tumor microenviron-
ment (e.g., by blocking the PD-1/PD-L1 axis) or by stimulating im-
mune cell activation (e.g., by cytokine interleukin [IL]-12 or IL-2
release) to eradicate cancer cells.17
Despite numerous successes in different types of cancer such as
melanoma, non-small cell lung carcinoma (NSCLC), urothelial carci-
noma, and Hodgkin’s lymphoma,18–20 immunotherapies with check-
point inhibitors have only been effective in a subset of patients,21 at
least in part due to the complex immunosuppressive interactions of
cancer cells within the tumor microenvironment.22 Certain combina-
tions of immunotherapeutics have shown synergistic effects, e.g., anti-
PD-1 with IL-12 or interferon (IFN)-g,23 but also severe side effects
upon systemic application, e.g., anti-cytotoxic T lymphocyte-associ-
ated protein 4 (anti-CTLA-4) with anti-PD-1.24
In contrast, immunotherapeutics delivered by viral or non-viral vec-
tors to the tumor site have provided increased efficacy with less severe
side effects due to the tumor-restricted expression of immunothera-
peutic combinations.25–27 Non-replicative high-capacity adenoviral
vectors (HCAdVs), also called helper-dependent vectors (HdVs) or
gutless adenoviral vectors, are especially well suited for the gene
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delivery of multiple transgenes due to their high packaging capacity
up to 36 kb,28 the efficient and long-lasting transgene expression of
up to 7 years,29 and the attenuated immune clearance of transduced
cells.30 The latter is largely a result of the absence of viral genes and
their products.
Despite these advantages, the broad use of HCAdVs is currently
hampered by the notoriously complex cloning and production
schemes of HCAdVs.31–33During HCAdV production, helper viruses
(HVs) provide sufficient viral proteins in trans to achieve high
HCAdV yields. HV particles are typically first-generation (FG)
adenoviral vectors derived from HAdV-C5 lacking the E1 and E3
gene clusters.34 Due to the high immunogenicity of HVs and the po-
tential interference of HV-expressed viral proteins with the target
cells, HV must be removed from any HCAdV formulation. To sup-
press HV particle formation, the packaging signal of the HV DNA
is typically flanked by loxP sites, which permits a Cre recombinase-
mediated excision of the HV packaging signal in HCAdV producer
cells, e.g., in the cell line 116.35 This conventional strategy reduces
HV contamination to 0.01%–0.2% of the HCAdV, that is, 100–
2,000 HV particles per million HCAdV particles (ppm).32,36
For gene therapy applications, the natural tropism of HAdV-C5 vec-
tors for coxsackievirus and adenovirus receptor (CAR) has been ab-
lated by genomic modifications to the adenovirus fiber knob.37 The
tropism of adenoviral vectors has been redirected to defined bio-
markers using genetically encoded tags, or exogenously added adapter
proteins.37,38 While genetic modifications can lead to virion insta-
bility and low vector yields,39 exogenously added adapters do not
affect vector production and thus allow for versatile use of the vector
in different cell types.39 Previously, our group has developed a
trimerized adapter that binds in a quasi-covalent manner to the
HAdV-C5 knob by coupling the trimerizing SHP domain of the
lambdoid phage 21 linked to a knob-binding designed ankyrin repeat
protein (DARPin).38 Cell specificity is then mediated by a second re-
targeting DARPin coupled to the SHP domain. Retargeting DARPins
against new proteins can be selected rapidly via ribosome display,40
produced efficiently in E. coli on a large scale, and the adapters con-
structed from them are then simply added to the virus.38 The receptor
specificity of a given virus can thus be changed rapidly.
Off-target infection of HAdV-C5 vectors, especially liver infection,
can further be reduced by genetic ablation of the hypervariable region
7 (HVR7) of the hexon, which facilitates blood factor X binding; how-
ever, HVR7 deletion also results in increased adenoviral depletion by
neutralizing antibodies.41,42 To decrease the rapid clearance of modi-
fied or unmodified HAdV-C5 by neutralizing antibodies following
systemic injection, our group has developed a trimerized single-chain
variable fragment (scFv)-based shield that covers the adenoviral sur-
face.43 The combined implementation of capsid mutation (DHVR7)
and exogenously added shield and adapter proteins increases tumor
specificity and transgene expression of non-replicative FG (E1 and
E3 deleted) adenoviral vectors upon intravenous and intratumoral
injection in murine models.43
To enhance the versatility of HAdV vectors, we have now designed a
system that facilitates the rapid and efficient assembly of multiple
transgenes into HCAdVs with very low HV contamination for gene
therapy approaches. Our platform iMATCH (integrated modular as-
sembly for therapeutic combinationHCAdVs) combines a highly effi-
cient assembly system with a novel purification strategy for gener-
ating combinations of HCAdVs, compatible with adenoviral
retargeting and shielding strategies that can be used for the specific
delivery of complex combinations of genes to target cells in a broad
range of diseases. We validated the efficacy of the iMATCH system
using reporter vectors as well as vectors harboring multiple immuno-
therapeutic genes for expression in cell culture and immune-compe-
tent murine tumor models.
RESULTS
A modular assembly system for combing therapeutic genes
The generation and production of HCAdVs has so far been cumber-
some, inefficient, and time-consuming.31 Overall, this is due to tech-
nical challenges in cloning of large (>28 kb) plasmids, which is
required in standard HCAdV preparations. To enhance the cloning
efficiency, we designed four size-optimized plasmids of 3–5 kb (pU-
niversal plasmids), each with an orthogonal expression cassette con-
taining one of the following constitutive promoters: cytomegalovirus
(CMV), EF1-a, SV40, or PGK (Figure 1A). The four promoters vary
in the efficiency of transgene expression relative to each other, de-
pending on the targeted cell.44 Expression levels of transgenes can
thus be tuned relative to each other and relative to the chosen pro-
ducer cell line. The expression cassettes were designed with minimal
sequence similarity to each other, to the HCAdV backbone and to the
HV genome, in order to reduce inter- and intra-vector homologous
recombination events. Notably, the number of payloads encoded on
the pUniversal plasmid is not limited by the number of promoters,
as polycistronic gene expression elements (e.g., 2A peptides45 or in-
ternal ribosomal entry sites [IRESs]46) can be utilized within each
open reading frame (ORF). Payloads encoding expression cassettes
were flanked in each pUniversal plasmid by a unique pair of restric-
tion sites and payload assembly overlaps (Figure 1A).
Upon restriction enzyme digestion, payloads encoded under the
CMV, EF1-a, or PGK promoter are released and can be integrated
into a linearized pUniversal plasmid of choice, which was beforehand
linearized with the same restriction enzyme pair. Payload integration
thus can be achieved either by cost-effective ligation or, alternatively,
by Gibson assembly.47 The assembly of multiple expression cassettes
was done sequentially or simultaneously, allowing for the assembly of
up to four expression cassettes on a single pUniversal plasmid within
1 day. Plasmid-encoded, correctly assembled payloads were selected
by antibiotic resistance and validated by sequencing, confirming a
cloning efficacy of more than 80%. To verify this approach, reporter
proteins were encoded within each expression cassette and combined
on a single plasmid. Cells transfected with a combination of pUniver-
sal plasmids containing all reporter expression cassettes showed
similar or greater protein expression compared to a mixture of single
reporter-encoding plasmid transfection (Figure S1).
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Rapid integration of gene combinations into a HCAdV genome
Once the desired payload combination is assembled, an additional set
of orthogonal restriction sites and overlaps (pC4HSU overlaps) on the
pUniversal plasmids can be utilized for the integration of the payload
combination into a well-characterized HCAdV backbone plasmid
(pC4HSU)35,48 via Gibson assembly (Figure 1B). Depending on the
payload size and the desired genome size of the HCAdV, the pUniver-
sal plasmids can be digested with PmeI/PacI, PmeI/XmaI, or PmeI
Figure 1. Schematic overview of the iMATCH platform
(A) Four separate cloning plasmids (pUniversal 1–4) were constructed, each with an orthogonal expression cassette with a distinct promoter (CMV, SV40, EF1-a, or PGK).
Unique restriction sites and payload assembly overlaps (shades of green) enable a rapid combination of payloads encoded on different pUniversal plasmids via ligation or
Gibson assembly (dotted lines). (B) Assembled payload combinations (green), released from the pUniversal plasmids using a different set of unique restriction sites (Figures
S2A and S2B), result in linear DNA fragments terminated by pC4HSU overlaps (red and shades of yellow), where pC4HSU is a HAdV backbone plasmid.35Depending on the
genomic size of the payload combination and the desired genome size of the HCAdV, different overlaps can be chosen (shades of yellow). In this manner, stuffer DNA (gray) of
different sizes (0, 4.5, or 9 kb) is excised from the HCAdV genome backbone plasmid (pC4HSU). The pC4HSU overlaps of the pUniversal fragments and the linearized
pC4HSU plasmid (dotted lines) thus allow the efficient generation of HCAdV genomes with defined genomic sizes via Gibson assembly. (C) HCAdV genomes (gray, green)
can be packaged into HCAdV particles with defined capsid modifications, e.g., modification of the hexon (blue) or fiber (violet) protein by administering different helper virus
(HV) vectors encoding themutated capsid proteins during HCAdV production. (D) HCAdV particles can be retargeted to defined cells via a chosen surface biomarker by using
a very tight-binding retargeting adapter that binds to the HAdV-C5 knob,38 here depicted in a simplified manner as bispecific DARPin retargeting adapters with two binding
modules connected by a flexible linker: The first binder (knob binding DARPin, black) binds trivalently to the trimeric adenoviral fiber knob and simultaneously blocks HAdV-C5
from binding to its natural receptors (CAR). A new cell tropism is introduced by the second binding entity (retargeting DARPin, red, green, or yellow) that facilitates the specific
binding to surface markers expressed on the cell of interest.
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(Figure S2A). Each resulting pUniversal fragment (Figure S2B) can be
integrated into a linearized pC4HSU plasmid with compatible over-
laps that was generated by AscI, AscI/NotI, or AscI/SwaI restriction
digest prior to assembly (Figure S2C). Linearization of the pC4HSU
plasmid releases either 0, 4.5, or 9 kb of “stuffer DNA”
(Figure S2D), which can be used to adapt the size of the resulting
HCAdV. This enables production of HCAdV particles with the
same genomic size and thus similar biophysical properties, indepen-
dent of the payload size.
To increase cloning efficiency, a unique restriction site (FspI) was
introduced into the antibiotic resistance gene of the pUniversal
plasmid (Figure S2A). Backbone fragments of pUniversal plasmids
that were used for payload release, but were re-circularized, can
lead to false-positive clones due to the presence of an antibiotic resis-
tance but a lack of payloads. For this reason, these fragments were di-
gested with FspI in parallel to the unique restriction enzymes required
for payload release. Upon Gibson assembly of the two fragments
(linearized pUniversal and pC4HSU) and transformation of E. coli
(Figure S2E), cloning efficiencies of up to 85% positive clones were
obtained for a representative construct (Figure S2F).
HCAdVs with unique capsid modifications
The absence of viral genes on the HCAdV genome requires that the
viral proteins are provided in trans by HVs for amplification of
HCAdVs. We designed multiple HVs with different capsid modifica-
tions, including anHVwithmodifications in the HVR7 of the HAdV-
C5 hexon to prevent factor X-mediated liver infection41 and an HV
vector encoding the HVR7 modification with an additional deletion
of the RGD motif from the HAdV-C5 penton that reduces integ-
rin-mediated cell infection (off-target infection49). These different
HVs readily enable the packaging of the HCAdV genome into a vari-
ety of different capsids (Figure 1C) without the need to genetically
modify the HCAdV genome. The use of different capsid modifica-
tions can be advantageous to modulate viral clearance, uptake, or to
reduce off-target transduction for gene therapy approaches.37 The
desired target cell specificity of HCAdV particles with genetic capsid
modifications was introduced by exogenously added retargeting
adapters38 following amplification and purification of HCAdVs, again
without the need to modify the original HCAdVs or HV vectors (Fig-
ure 1D). Retargeted HCAdV particles were additionally covered by a
shield, formed by a trimerized scFv to prevent off-target infection and
HCAdV clearance by neutralizing antibodies.43
Generation of HCAdVs with minimal HV contamination
HV contamination of HCAdV preparations must be kept as low as
possible, due to the unavoidable viral gene expression from HV,
which causes an increased adaptive immune response against HC-in-
fected recipient cells.30 On the other hand, HVs are required for
HCAdV production (Figure 2A), as they provide viral proteins in
trans for the packaging of HCAdV genomes at the necessary balanced
concentrations and in sufficient yields. To minimize HV contamina-
tion, we designed HVs that had minimal genomic similarity to the
HCAdV, even including a modified encapsulation signal,35 which
in addition to reduced genetic similarity, packaged at a lower effi-
ciency than did the wild-type (WT) packaging signal of the HCAdV.
Furthermore, our HV vectors were designed to have a genome size at
the upper range of adenoviral packaging capacity (37.5 kb) to reduce
the risk of generating fully replication-competentWT adenoviral vec-
tors. The formation of competentWT adenoviral vectors can occur by
E1/E3 recombination of HV vectors with E1 located on the chromo-
some of the producer cell line. The genomic size difference between
the HCAdV (28–30 kb) and the HV (37.5 kb) also facilitates a suffi-
cient separation of both vectors in subsequent CsCl density purifica-
tion. Furthermore, we used the packaging cell line 116 for HCAdV
amplification, which was specifically created to improve HCAdV pro-
duction yield and purity.36 The cell line 116 was previously selected
for increased HCAdV amplification and its high levels of Cre recom-
binase.35 Cre recombinase permits the removal of the loxP-flanked
HV packaging signal and thus renders the HV DNA non-
packageable.
The combination of this HCAdV genome, HV vectors, and packaging
cell line resulted in efficient amplification of the HCAdVs utilizing
our platform (Figure S3). HCAdVs are traditionally purified via
two density gradients, a first two-step gradient (1.25 and 1.35 g/
cm3) in which the cell lysate, cell debris, and empty particles are sepa-
rated from the viral particle, and a second continuous gradient (1.33
g/cm3) in which the HCAdV particles are separated from the HVs.
Instead of utilizing a traditional continuous gradient32,36 as the sec-
ond purification step, we used a discontinuous four-step gradient
ranging from 1.29 to 1.35 g/cm3 (Figure 2B), which led to a visible
separation of the desired HCAdV (30 kb) from the HV particles
(37.5 kb; Figure 2C).
Purified HCAdVs with the capsid modifications described above en-
coding a reporter protein (GFP) showed dose-dependent reporter
expression with non-detectable HV reporter protein expression
(mCherry), even under very high multiplicities of infection (MOIs;
Figures 3A–3D; Figure S4A). Sensitive quantification of HV contam-
ination via quantitative polymerase chain reaction (qPCR)
(Figure S4B) revealed unprecedented low HV contaminations of
0.00001%–0.00012%, or 0.1–1.2 ppm, of HV of HCAdVs generated
with the iMATCH platform (Figure 3E). Other HCAdV production
and purification protocols typically report 0.01%–0.2% HV contam-
ination,32,36 which is 2–4 orders of magnitude higher than that ob-
tained with the iMATCH platform.
In addition to the high purity of the HCAdV particles, the iMATCH
platform provided high yields of HCAdVs (Figure 3E) sufficient for
multiple in vivo studies (see below). On average, 2  1011 genomic
HCAdV particles per production from 3  108 cells with a ratio of
24 genomic HCAdV particles per transducing unit were obtained
(averaged across 11 preparations). HCAdV yields were not affected
by the number of transgenes encoded on the vectors, i.e., single
payload HCAdVs yielded on average 1.98  1011 genomic HCAdV
particles, similar to payload combination vectors (e.g., RMP1-
14_IL-12_IL-2) with on average 2.02  1011 genomic HCAdV
www.moleculartherapy.org
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particles. Furthermore, negative staining of purified HCAdV viral
particles with electron microscopy revealed intact HCAdV particles
free from adeno-associated virus (AAV) and other contaminants
(Figure 3F).
Cell- and organ-specific targeting of HCAdVs mediated by
exogenously added shield and retargeting adapters
In order to test whether retargeting and shielding strategies previously
developed for FG adenoviral vectors are compatible with HCAdVs
generated by the iMATCH platform (Figure 4A), we transduced
EMT6 cells that express HER2 (EMT6-HER2) in vitro (Figure 4B)
or in vivo (Figures 4C–4E) with identical MOIs of HER2-retargeted
and shielded FG or HCAdV reporter vectors encoding a firefly lucif-
erase gene. All HCAdVs and FG adenoviral vectors used in this and
the following in vitro and in vivo studies contained an HVR7 modi-
fication to reduce factor X binding.41 Transgene expression was
only detected from cells infected with adenoviral vectors that were
incubated prior to infection with retargeting adapters for HER243
and shield (Figure 4B). Cells transduced with naked virus, and those
transduced with virus incubated with shield and adapters that lacked
Figure 2. High-capacity adenoviral vector amplification and purification
(A) HCAdV producer cells, e.g., the cell line 116, were infected with HV and transfected with linearized HCAdV genomes (adenofection) in passage 0 (P0). During HCAdV
amplification (P0–P4), HV amplification is inhibited by Cre-mediated excision of the HV packaging signal; thus, HV particles are re-administered to the cell lysate before
infecting the next passage. After amplification, adenoviral particles are released from the 116 cell line and purified by two CsCl density purification steps. HCAdV (green curve)
and HV (red curve) genomes are quantified by qPCR after amplification and purification. (B) Adenoviral particles (orange band) are separated from cell debris, cell lysate, and
empty particles on a two-step CsCl gradient (left) and subsequently applied to a four-step gradient (right) for further separation of HCAdV particles (green band) from HV
particles (red band). (C) A GFP-expressing HCAdVwas purified. After the first centrifugation step (left), three distinct white bands are visible in the following order (from top-to-
bottom): cell debris, empty viral particles, and mature viral particles. Notably, the cell lysate above the CsCl gradient is colored green from the presence of soluble HCAdV
reporter (GFP). Following extraction of the band containing mature particles and application to the second CsCl gradient (right), a prominent upper band containing HCAdV
particles (30 kb) is separated from a very faint lower HV band (37.5 kb).
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the retargeting DARPin but still contained the knob-binding DARPin
(blocked vectors), showed no elevated transgene expression
compared to PBS-treated cells. Notably, transgene expression medi-
ated by the HER2-retargeted and shielded FG vector was equal in
terms of transgene expression induced by the HER2-retargeted and
shielded HCAdV.
We further monitored gene delivery via retargeted and shielded FG
vectors and HCAdVs in an immunocompetent mouse model. For
this purpose, EMT6-HER2 cells were injected into the mammary
gland of female BALB/c mice. Seven days later, tumor-bearing mice
received an intratumoral application of virus with 3  108 trans-
ducing units of either HER2-retargeted and shielded FG vectors or
HCAdVs (Figure 4C). Luciferase activity was measured in live ani-
mals using in vivo imaging 1 day post-injection (Figure 4D) following
intraperitoneal injection of luciferin. The luciferase signal was only
detectable within tumors treated with adenovirus but not in the un-
treated control animals. Quantification of the in vivo luciferase signals
revealed no significant differences between FG vectors and HCAdVs
(Figure 4E), in agreement with in vitro results. Following measure-
ments in live animals, mice were sacrificed, and various tissues
were harvested, lysed, and analyzed for luciferase activity. Transgene
expression was indeed limited to the tumor, with no significant signal
detectable in all other organs for both FG- and HCAdV-treated mice.
No significant difference in luciferase activity could be detected be-
tween FG vectors and HCAdVs in the tumor (Figure 4F).
Expression of multiple therapeutic payloads from a single
HCAdV
Next, we assessed payload transcription and expression from a single
HCAdV encoding multiple therapeutic payloads and compared it to a
mixture of HCAdVs encoding the same payloads as single payloads
per vector. We generated an immunotherapeutic combination of
three payloads, a murine anti-PD-1 antibody (RMP1-14) and two cy-
tokines (IL-12 and IL-2). This combination was chosen due to the
strong synergistic effects between anti-PD-1 and IL-12 and between
anti-PD-1 and IL-2, as compared to single-agent treatments in previ-
ous preclinical and clinical studies.23,50 The number of total trans-
ducing viral particles was kept equal for each treatment group in
the following in vitro and in vivo studies, in order to equalize the
immunologic response to adenoviral particles, which was deemed a
relevant factor in studies with non-human primates and human
patients.51
Single payload-containing HCAdVs (Ad_RMP1-14, Ad_IL-12, or
Ad_IL-2) and an HCAdV encoding all three payloads (triple vector)
were generated via the iMATCH platform. According to the thera-
peutic windows of the payload, the antibody RMP1-14 was encoded
Figure 3. Production of HCAdVs in high purity and quantity
(A–C) A549 cells were infected (A) with HCAdVs carrying the wild-type HAdV-C5 capsid, (B) with a modified hexon-encoding a HVR7 mutation,41 or (C) with modified hexon
and fiber proteins containing the HVR7 hexon mutation and the deletion of the RGD fiber motif. All HCAdVs showed titratable payload reporter (GFP) expression with no
detectable HV reporter (mCherry) signal. (D) As a control, purified HV showed comparable reporter expression as HCAdVs. (E) Quantification of HCAdV and HV genomic
particles via qPCR of purified HCAdVs revealed unprecedented purity of produced HCAdV particles of 0.00001%–0.00012%, or 0.1–1.2 ppm. Furthermore, HCAdVs were
generated in high quantities of 0.3–1.5  1011 genomic HCAdV particles from 2–3  108 cells. (F) Transmission electron microscopy (TEM) micrographs analyzed with
negative staining of purified HCAdVs showed intact HCAdV particles free from AAV and other contaminants. Error bars in (A)-(D) represent SEM with n = 3.
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under the control of a strong CMV promoter. In contrast, the two cy-
tokines IL-12 and IL-2, which are highly effective already at low pico-
molar concentrations, were encoded under the control of a weaker
SV40 promoter (Figure 5A). The payload design is described in
further details in Materials and methods. Due to the toxicity of IL-2
at high concentrations,52 IL-2 was encoded under the translational
control of an encephalomyocarditis virus (EMCV)-IRES53 in the tri-
ple and single payload HCAdV.
Following infection of A549 cells, an overall correlation between tran-
script numbers (Figure 5B) and protein secretion (Figure 5C) could be
observed. The triple HCAdV showed a small, albeit not significant,
reduction of transgene transcription and expression levels for pay-
loads encoded under the CMV promoter (RMP1-14), as compared
to the single payload vector (Ad_RMP1-14) alone. The mixture of
single payload vectors showed a 3-fold decrease in CMV-driven
RMP1-14 expression, compared to the single Ad_RMP1-14 vector,
which was proportional to the reduced copy numbers of the
RMP1-14 transgene in the mixture. The CMV promoter generated
an average of 6.5 CMV-driven mRNAs (RMP1-14) per GAPDH
mRNA, compared to 0.7 SV40-driven (IL-12) mRNA per GAPDH
in the single vector condition, i.e., a roughly 9-fold difference. This in-
dicates that the CMVpromoter has an increased transcriptional activ-
ity compared to the SV40 promoter in A549 cells. A decrease of SV40-
driven transgene (IL-12 and IL-2) transcription and expression could
be observed in the presence of the stronger CMV promoter in the tri-
ple HCAdV and in the mixture of single payload vectors. The absence
of a transgene upstream of the EMCV-IRES and downstream of the
SV40 promoter in the Ad_IL-2 HCAdV (Figure 5A) led to a decrease
in IL-2 transgene transcription and expression compared to the triple
HCAdV, which encoded IL-12 upstream of the EMCV-IRES.
We acknowledge that absence of a gene upstream of the IRES in front
of IL-2 in the single vector might impede the comparison of the com-
bination HCAdV and the mixture of single payload vectors. There-
fore, we also analyzed transcription and expression of a second
Figure 4. Retargeted and shielded HCAdVs showed
comparable gene expression and biodistribution to
FG vectors
(A) First-generation (FG) vectors and HCAdVs were re-
targeted via a trivalent knob-binding bispecific DARPin
retargeting module (black and light brown) and coated
with a trimeric scFv shield (gray). (B) EMT6-HER2 cells,
infected in vitro by shielded and HER2-retargeted FG
vectors or HCAdVs that encoded a luciferase reporter
gene, both showed significantly elevated levels of lucif-
erase activity. Only background levels of luciferase activity
were detected from untreated cells (PBS), cells infected
with untreated HCAdVs (naked virus), and cells infected
with HCAdVs, which carry a blocking adapter (no HER2-
retargeting DARPin) and the shield (blocked). No signifi-
cant differences between luciferase activity mediated by
FG vectors and by HCAdVs could be detected in vitro.
Luciferase activity was measured from lysates of three
separately transduced cell populations, which were
measured in technical duplicates (n = 6). (C) EMT6-HER2
tumor-bearing mice were injected intratumorally with re-
targeted and shielded HCAdVs or FG vectors and lucif-
erase activity was measured 24 h after infection with an
in vivo imaging system after intraperitoneal injection of
luciferin substrate. (D) Vector-treated mice showed
detectable luciferase activity, while no luciferase signal
was detected in untreated control mice. (E) Quantification
of the luciferase signal from (D) revealed no significant
differences of transgene expression mediated by retar-
geted and shielded vectors between the HCAdV or FG
type. (F) Following organ harvest and lysis, luciferase
signals were measured from multiple tissues, including
tumor, draining lymph nodes (dLNs), non-draining lymph
nodes (ndLNs), spleen, liver, kidney, lung, and heart as
described for (D). Significantly elevated levels of luciferase
activity could only be detected in tumor tissues. Three
mice per group were used for studies presented in (D)–(F).
Statistical analyses were done with a two-way ANOVA
test. *p < 0.1, **p < 0.01, ***p < 0.001. n.s., not significant
(p > 0.9). All error bars represent SEM.
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combination (RMP1-14 and IL-12) in the absence of IL-2 (Fig-
ure S5A). In analogy to the triple combination, a decrease of SV40
transgene (IL-12) expression in the presence of a CMV promoter
was also observed in the dual combination (Figure S5B). CMV-medi-
ated (RMP1-14) expression was not significantly reduced in the dual
combination by SV40-driven co-expression of IL-12 (Figure S5C).
Despite the small number of payloads in the tested combinations,
we could observe that the transgene (RMP1-14 or IL-12) expression
from a combination HCAdV was less reduced with increasing trans-
gene numbers, compared to a mixture of single payload vectors (Fig-
ure S6), provided that the total viral particle numbers are constant. In
conclusion, a HCAdV encoding multiple transgenes showed similar
or even improved in vitro transgene transcription and protein secre-
tion compared to a mixture of single payload HCAdVs.
In vivo efficacy of high-capacity adenovirus combination
immunotherapy
To determine the in vivo efficacy of the combination triple HCAdV
encoding RMP1-14, IL-12, and IL-2, we administered iMATCH vec-
tors containing either a single payload or the combination of all three
payloads intratumorally to immunocompetent C57BL/6 mice bearing
subcutaneous B16-D5-HER2 tumors (Figure 6A). B16-D5-HER2
cells are highly aggressive melanoma cells that stably express HER2
and form immune-excluded tumors in C57BL/6 mice. The triple
combination led to a successful tumor rejection, while mice treated
with a single payload vector only showed a delay in tumor growth
(Figure 6B). Tumor growth curves for individual mice of each treat-
ment group are depicted in Figures S7 and S8. The improved tumor
control of the triple vector resulted in prolonged survival of these
mice compared to mice treated with single payload vectors or un-
treated mice (Figure 6C). IL-12 encoded on a single payload vector
caused the second highest survival rate, while IL-2 as a single payload
vector showed no improved survival compared to the untreated
group.
Next, we compared the triple combination vector against the mixture
of single payload vectors. Both groups successfully decreased tumor
growth (Figure 6D), compared to the untreated group, and showed
prolonged survival (Figure 6E). Tumor regression and prolonged sur-
vival were increased in the triple vector treatment group compared to
the mixture of single payload vectors. Overall, all mice treated with
payload-containing HCAdVs, except for the IL-2 single payload vec-
tor, led to a significant reduction in tumor burden compared to the
untreated group (Figure 6F). Although the treatment with the triple
Figure 5. In vitro expression of a triple payload
combination encoded on a triple vector or on
different single payload HCAdVs
(A) RMP1-14 (CMV promoter), IL-12 (SV40 promoter),
and IL-2 (SV40 promoter) were encoded each on a
separate HCAdV (blue, violet, and light red) or together on
a combination triple HCAdV (green). (B and C) Tran-
scription (B) and secretion (C) levels of RMP1-14 (left
panel), IL-12 (middle panel), and IL-2 (right panel) were
measured in A549 cells 72 h after infection with 10 TU/
cell. Cells were infected with either a single payload vector
(left bar), the triple HCAdV (middle bar), or a mixture of
single payload vectors (right bar). In all cases, the same
total viral particle numbers were used. Transcription and
translation levels of RMP1-14 (CMV promoter) were
decreased only slightly upon co-expression of IL-12 and
IL-2 from an SV40 promoter in the triple vector. In the
mixture of single vectors, the gene dosage is one third,
and this is reflected well in the transcript and protein level.
Payload transcription and expression from the weaker
SV40 construct was significantly reduced by the pres-
ence of the stronger CMV promoter independent of
whether both promoters were located on a combination
vector (triple vector) or on different vectors (a mixture of
single payload vectors). The observed reduction of SV40-
derived gene expression was in both conditions over-
proportional to the number of transgenes delivered (more
than a 3-fold reduction). As an exception, IL-2 transcrip-
tion and expression from the triple vector was drastically
increased, compared to the single Ad_IL-2 vector, due to
the lack of a transgene upstream of the IRES in the single
Ad_IL-2 vector. Overall, transcription and protein secretion levels of the encoded payload correlated well. In vitro protein secretion was determined from supernatants of
three separately transduced cell populations, which were measured in duplicates in an antigen capture ELISA setup. Transcription levels were determined from A549 cell
lysates of three separately transduced cell populations measured in duplicates via real-time PCR. Statistical analysis was donewith a two-way ANOVA test. **p < 0.01, ***p <
0.001, ****p < 0.0001. n.s., not significant (p > 0.9). All error bars represent SEM.
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vector showed decreased tumor regression, it was not significantly
different from tumor regression induced by IL-12 single vector treat-
ment or treatment with a mixture of all three single payload vectors.
The IL-12 single payload vector, the triple vector, and the mixture of
single payload vectors led to similar improved survival compared to
the untreated group (Figure 6G); that is, there was no significant dif-
ference between triple vector treatment and treatment with a mixture
of single payload vectors or IL-12 single treatment. Neither treatment
led to a significant change in the body and physical scoring of themice
(Figure S9).
Although the single IL-2 HCAdV showed no improvement in tu-
mor control or survival, it is possible that the increased expression
of IL-2 from the triple vector could positively influence the in vivo
efficacy of the triple vector in comparison to a mixture of single
Figure 6. In vivo efficacy of a triple payload
immunotherapy HCAdV
(A) Tumors were injected four times intratumorally with
retargeted and shielded HCAdVs 10 days after injection of
B16-HER2 cells at 2-day intervals. All treatments were
given with the same total viral particle number (3 108 TU
per injection). Tumor volumes were measured for 60 days
after cell injection. (B–E) Mice treated with a triple vector
showed improved tumor regression (B) and survival (C)
compared to single payload vector treatment and
compared to a mixture of single payload HCAdVs (D and
E). (F) All payload-containing vectors except the Ad_IL-2
single vector showed a significant decrease of tumor
volume with no significant differences between the triple
vector and the mixture of single payload vectors 24 days
after tumor cell injection. (G) The average survival was
significantly improved for the Ad_IL-12 vector, the triple
vector, and the mixture, compared to the untreated
group, with no significant differences between the triple
vector and the mixture. Treatment groups in (B) and (C)
consisted of 5mice, except for Ad_Empty and Ad_RMP1-
14 (n = 4), and groups of (D) and (E) consisted of 11 mice.
Data from (B) and (D) were pooled for (F), and data from
(C) and (E) were pooled for (G). Statistical analysis of (F)
and (G) was donewith a two-way ANOVA test including all
treatment groups. Indicated significances in (F) and (G)
refer to the untreated control (upper lane) except for the
separate comparison of the three samples Ad_IL-12,
mixture of vectors, and triple vector (lower lane). *p < 0.1,
***p < 0.001, ****p < 0.0001. n.s., not significant (p > 0.9).
Error bars in (B), (D), and (F) represent SEM.
payload vectors. For this reason, we performed
an additional study with a dual vector encod-
ing RMP1-14 and IL-12 and compared the
dual vector with a mixture of single payload
RMP1-14 and IL-12 vectors. The dual vector
and the mixture of the two single payload vec-
tors led to significantly decreased tumor
growth (Figure S5D) and improved survival
(Figure S5E) compared to the untreated group
with no significant differences between the dual vector and the
mixture of the single payload vectors. In conclusion, the mixtures
of single payload vectors and the respective combination HCAdV
showed virtually identical therapeutic efficacy in tumor regression
and survival in vivo.
DISCUSSION
So far, more than a dozen different gene therapy-based therapeutics
have been approved in different countries for treating cancer, blind-
ness, immune disorders, or neurological failure, and an increasing
number of preclinical and clinical gene vector trials are currently
ongoing. More than 400 adenoviral gene vectors have been tested
in these trials.54Nonetheless, a system for the rapid and efficient gen-
eration of high-capacity adenoviral gene vectors for cell-targeted gene
delivery of therapeutic combinations is still missing.55
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Here we designed the iMATCH platform, which enables the rapid as-
sembly ofmultiple therapeutic genes, encoded under the control of four
different constitutive promoters (CMV, SV40, EF1-a, or PGK) on a
size-optimized pUniversal cloning plasmid. The cell type-specific tran-
scription activity of these promoters allows for a defined transgene
expression tailored to the targeted cell type and the required transgene
concentration.44 In this highly modular system, each of these pro-
moters could also be exchanged to tissue-specific or otherwise regulat-
able promoters. Promising combinations of immunotherapeutics,
vaccination agents, or gene modifier can be generated with the pre-
sentedmodular assembly system rapidly and tested in vitro as plasmids,
before starting time- and cost-intensive vector production. Moreover,
because of the non-covalent nature of the targeting adapter, this ex-
tends to the search for the optimal surface receptor and its epitope,
which can also be achieved without producing a new vector. Once
the most suitable combination is found, the previously laborious and
time-consuming integration of therapeutic combinations into
HCAdVs31 can be avoided by the iMATCH system, with which cloning
efficiencies of up to 85% were achieved.
The genomic size of adenoviral vectors can influence packaging ef-
ficiency and thus the yield of functional virions, but also their bio-
physical properties, for instance thermostability.56 To exclude that
suboptimal vector size influences the efficacy of combinational
HCAdVs, the iMATCH system was designed to generate HCAdVs
with defined genomic sizes by exploring unique sets of restriction
enzymes and overlaps for Gibson assembly. Utilizing this versatile,
efficient cloning system, HCAdVs with multiple therapeutic genes
can be cloned, amplified, and purified from existing transgene con-
structs with the iMATCH system within 3 weeks. This reduces the
production time for therapeutic HCAdVs by half, compared to pre-
viously reported protocols (43 days),32 enabling a faster screening of
therapeutic combinations, and allowing the production of several
HCAdVs in parallel.
HV contamination of purified HCAdVs should be minimized due to
the high immunogenicity of HV particles and the potential interfer-
ence with the target cells.30 Although multiple systems have been
developed to reduce HV contamination of HCAdV preparations in
the past,32,35,36,57 HV contamination is still a major issue in many ap-
plications, limiting the broad use of HCAdVs. We achieved unprece-
dented low amounts of HV contamination of 0.00001%–0.00012%, or
0.1–1.2 ppm, HCAdV particles, using optimized HVs and purifica-
tion protocols, which is an improvement of 100- to 2,000-fold to pre-
viously published HCAdV purification protocols, which have re-
ported 0.2%–0.01% HV contamination.32,36 We hypothesize that
the residual absolute HV contamination level in our HCAdV prepa-
rations is constant under the established conditions (<100 HV ge-
nomes per mL) and that the relative contamination therefore varies,
depending on theHCAdV yield obtained. Due to the reduced produc-
tion time and the repeatedly low HV contamination of the iMATCH
platform, this approach is adaptable and straightforward, and it might
thus be widely used to achieve HCAdV production of the highest
quality.
Furthermore, our results indicate that transgene combinations of in-
terest can be systematically screened as combinations of FG vectors or
HCAdVs encoding single payloads. Promising combinations can
then be encoded on a single HCAdV with a packaging capacity of
up to 36 kb. We suggest this procedure as the most efficient strategy,
based on the following findings: (1) retargeted and shielded HCAdVs
and FG vectors showed similar protein expression in vitro and in vivo
as well as similar biodistribution; (2) expression and transcription
from a combination vector was equal to or higher than from amixture
of single payload vectors when comparing the same total particle
numbers; (3) transgene expression from a combination vector
decreased less drastically with increasing numbers of transgenes,
compared to a mixture of single payload vectors; and (4) combination
HCAdVs gave rise to comparable in vivo tumor regression and sur-
vival than themixture of the respective single payload vectors, notably
in an aggressive syngeneic immune-excluded tumor model (B16-
HER2 in C57BL/6 mice).
We noticed that the concentration of the most effective single payload
(IL-12 encoded under a SV40 promoter) was reduced by the presence
of a transcriptionally more active promoter (CMV), independent of
whether the transgenes were encoded on a combination vector or
administered as a mixture. The downregulation of one promoter by
a second cis-encoded promoter was also previously observed for
retroviral vectors.58 As a consequence, we recommend adapting the
choice of promoter for each of the payloads after an initial in vitro
or in vivo assessment with the single payload vectors. Utilizing this
procedure, it may be possible to further increase the potency of the
tested, synergistic RMP1-14, IL-12, and IL-2 combination. Neverthe-
less, we emphasize that the presented studies were designed to inves-
tigate the suitability of combination HCAdVs for the delivery of com-
plex immunotherapy combinations, rather than establish a pre-
clinical argument for the particular anti-PD1, IL-12, and IL-2 combi-
nation and their promoters and expression levels.
The clinical approval of combination treatments such as in immuno-
therapies in a variety of different indications, for instance in metasta-
tic melanoma, advanced renal cell carcinoma, and metastatic colo-
rectal cancer,59 emphasizes that the preclinical testing of
combination HCAdVs in multiple different cancer or disease models
would be beneficial. However, the systemic administration of some of
these combinations as systemically administered proteins has led to
adverse side effects,24 highlighting the need for cell- or organ-specific
production of these agents. This has been a key motivation for devel-
oping the iMATCH platform. Cell-specific transduction of adenoviral
vectors can be achieved via genetic modifications,37 which requires
the reconstruction and reproduction of the same combination
HCAdV for each disease model and can lead to virion instability
and reduced production yields.39 Furthermore, many strategies would
not be able to generically target any surface receptor of choice.
For this reason, HCAdVs generated by the iMATCH system were de-
signed to be compatible with any exogenously added retargeting
adapter for HAdV-C5 vectors. The large library of existing DARPins,
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the rapid selection of new DARPin adapters against surface
markers,40 and the efficient production of DARPin-based retargeting
adapters in bacteria38 are advantages unique to the retargeted strategy
presented herein. In addition, due to the high abundance of pre-exist-
ing antibodies against HAdV-C560 in the population of many coun-
tries, covering of iMATCH-generated HAdV-C5 vectors with the
previously described shield that has been shown to reduce neutral-
izing antibody binding to HAdV-C5 FG vectors43 would be beneficial
for therapeutic uses. Alternatively, HCAdVs of other serotypes with a
lower pre-existing immunity can now be developed for clinical pur-
poses4 based on the strategy described herein.
In conclusion, we think that the rapid production of combination
HCAdVs in high quantity and purity, the compatibility with estab-
lished cell-specific targeting strategies, and the broad variety of
payload molecules that can be encoded on HCAdVs make the iM-
ATCH platform an attractive vector-developing tool for multiple
research fields.
MATERIALS AND METHODS
Plasmid, cells, and mice strains
The plasmid pAdEasy-1 was obtained from Agilent Technologies61
and modified as described below. The pC4HSU plasmid was pur-
chased from Microbix and originally developed by Sandig et al.35
The murine cell line EMT6-HER2 was generated as previously
described.62 Briefly, murine EMT6 cells were modified for constitu-
tive expression of HER2. The B16-D5-HER2 murine cell line was
kindly provided by Louis Weiner.63 A poorly immunogenic subclone
of murine B16 cells, D5, was modified to constitutively produce
HER2. The human cell line 116 was kindly provided by Philip Ng
and cultured as recommended.36 The remaining cell lines were pur-
chased from the vendor ATCC and cultivated according to the pro-
vider’s recommendations. Cells were passaged no more than 15 times
from the original stocks. C57BL/6 and BALB/c mice were bred in-
house at the University Hospital of Basel (Basel, Switzerland). Ani-
mals were housed under specific pathogen-free conditions. All animal
experiments were performed in accordance with Swiss federal
regulations.
Plasmid constructions
The helper viral vector pmCherry-HV plasmid was generated by re-
placing the natural packaging signal of the pAdEasy-1 vector with a
loxP-flanked modified encapsulation signal derived from Sandig
et al.35 and a mCherry reporter under the control a PGK promoter.
The plasmid pmCherry-HVR7 was derived from pmCherry-HV by
inserting four mutations into the hypervariable loop 7 of the hexon
(I421G, T423N, E424S and L426Y) as previously described.43 Further
deletion of the RGD region of the fiber protein generated the plasmid
vector pmCherry-HVR7-DRGD. All cloning steps involving helper
viral plasmids were carried out by homologous recombination as re-
ported in previous studies.43 The pUniversal plasmids were generated
de novo using Gibson assembly47 by combining the pUniversal back-
bone fragment that encodes the origin of replication and ampicillin
resistance derived from the pcDNA3.1(+) plasmid (Invitrogen)
with gene fragments containing expression cassettes synthesized by
GeneArt (Thermo Fisher Scientific). Each expression cassette consists
of a unique pair of promoters and terminators (e.g., SV40 promoter +
SV40 terminator, CMV promoter + bovine growth hormone termi-
nator, EF1-a promoter + human growth hormone terminator, or
PGK promoter + human b-globin terminator), each with a set of
unique restriction sites for payload insertion (e.g., EcoRI and BamHI
or EcoRI and XbaI).
Payload design
The rat anti-PD1 antibody clone RMP1-14, an immunoglobulin of
type IgG2ak, whose sequence was identified from hybridoma
sequencing (Bio X Cell), was converted to a chimeric mouse IgG2ak
antibody with rat variable domains. The mouse IgG2a*01 heavy chain
(HC; IMGT: IGHG2A*01; accession no. V00825)64 and the k light
chain (LC; IMGT: IGKC*01; accession no. V00807) were used as scaf-
folds. The following mutations were included in the HC: (1) the CH2
glycosylation site was mutated to alanine (N297A) to impair FcgR
binding; (2) effector functions were further ablated by introducing
L234A, L235A, and P329G mutations to the CH2 domain;65,66 and
(3) a cloning site was added that introduces a K115S mutation into
the CH1 domain. Optimized H5 and L1 leader sequences were used
for HC and LC secretion,67 respectively. Chains were expressed using
a F2A68,69 sequence with an optimized furin site (RKRR)70 for expres-
sion from a single open reading frame, with the orientation HC-F2A-
LC as described previously.71
The murine IL-12 gene was generated from translated GenBank
cDNA sequences for IL-12B/p40 (GenBank: BC103608.1) and IL-
12B/p35 (GenBank: BC146595.1) connected by F2A peptide as above,
and the murine IL-2 gene was created from the translated GenBank
cDNA sequence (GenBank: NM_008366.3). The cytokine genes
included their native signal sequences. All payload constructs were
codon-optimized for mouse expression and synthesized by GeneArt
(Thermo Fisher Scientific).
HCAdV generation
Helper viral vectors were generated in the human cell line HEK293 as
previously described; they originate from the HV plasmids
pmCherry, pmCherry-HVR7, and pmCherry-HVR7-DRGD.61
HCAdVs were amplified as described in detail by Ehrke-Schulz
et al.72 Following three wash steps with PBS, the collected cells
from 15  15-cm dishes were lysed by three freeze-thaw cycles using
a 37C water bath and liquid nitrogen. The cell lysate was cleared by
8 min of centrifugation at 500  g, 4C. The cell supernatant was
applied on the first CsCl gradient consisting of two steps, 1.25 and
1.25 g/cm3 CsCl. The remaining cell pellet was washed with 2 mL
of PBS, and the supernatant was additionally applied on the first
CsCl gradient. The lower viral band of the first CsCl gradient was ex-
tracted after 2 h of centrifugation at 12C, 226,000  g with a syringe
and transferred to a second, four-step CsCl gradient, consisting of
four steps ranging from 1.29 to 1.35 g/cm3. The lower-density
HCAdV particles formed an upper band and were extracted from
the second gradient after 18–24 h of centrifugation at 12C,
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226,000  g. Following dialysis in dialysis buffer of 20 mM HEPES
(pH 8.1), 150 mM NaCl, and 1 mM MgCl2, glycerol was supplied
to the viral solution reaching a final concentration of 10% prior to
viral storage at 80C.
Genomic and transducing particle determination
For transducing particle determination, 0.5  105 A549 cells per well
were seeded in a 24-well plate 24 h prior to infection. Cells were trans-
duced with 3 mL of purified HCAdVs and incubated for 2 h at 37C.
The infection medium was aspirated, and the cells were washed with
0.5 mL of PBS. Following trypsin digest, detached cells were washed
once with 1 mL of PBS, 1,000 g, 5 min, 4C. For viral genome quan-
tification during HCAdV amplification, viral genomes were extracted
from collected cells using a DNA isolation kit (Genekam, SB0071),
following the manufacturer’s protocol. Viral genomes of purified
HCAdV samples were quantified directly from the viral solution
following a 5-min inactivation step at 80C. HCAdV genomes were
quantified by qPCR with specific primers (50-TCTGCTGGTTCACA
AACTGG-30, 50-TCCTCCCTTCTGTCCAAATG-30) and a specific
probe (50-CGCCTTCTCCAGCATCCCGA-30) in a multiplex reaction
with HV-specific primers (50-GAATAACAAGTTTAGAAACCCCAC
GGTGG-30, 50-GTTTGACCTTCGACACCTATTTGAATACCC-30)
and probe (50-TGACATCCGCGGCGTGCTGGACAGG-30). All reac-
tions were performed using PrimeTime gene expression master mix
(Integrated DNA Technologies, 105571), and HCAdV and HV signals
were normalized to the passive dye rhodamine-X (ROX). All qPCR
primer and probes were generated with the double quench technology
by Integrated DNA Technologies. The qPCR reaction was performed
and analyzed as described previously.72
Reporter quantification in HEK293 cells
HEK293 cells were seeded at 10,000 cells per well in a 96-well plate,
24 h prior to infection. Cells were infected with a defined number
of viral particles and harvested 72 h after infection. Following three
wash steps with 1 PBS, fluorescence protein expression was quanti-
fied with a BD LSRFortessa cytometer. The Alexa Fluor 488 channel
was used for detecting GFP expression, and the phycoerythrin (PE)-
Texas red channel was used for detecting tdTomato expression after
gating on single cells.
Electron microscopy analyzed with negative staining of high-
capacity adenoviral particles
Purified HCAdV (encoding no transgene) was diluted to a concentra-
tion of 1 mg/mL. Next, 10 mL of droplet HCAdV samples was spotted
on copper grids (300-mesh, glow-discharged) for 30 s, then overlaid
with 10 mL of droplets of 2% uranyl acetate for 1 min. The excess ura-
nyl acetate was removed with filter paper. A CM100 transmission
electron microscope (Thermo Fisher Scientific) with an acceleration
voltage of 80 kV and an Orius 1000 digital camera (Gatan) were
used to examine the grids.
In vitro retargeting of adenoviral vectors
EMT6-HER2 cells were seeded with 1 105 cells per well of a 24-well
plate, 24 h prior to infection. FG adenoviral vectors or HCAdVs en-
coding firefly luciferase under the control of a CMV promoter were
incubated either with a retargeting G3 adapter38 containing human
HER2 specificity and a shield (termed “retargeted”), a blocking
adapter that only contained the knob-binding DARPin but no retar-
geting DARPin and a shield (“blocked”), or without any retargeting
adapter or shield (“naked virus”) for 1 h at 4C. The ratio of viral
knobs to retargeting adapter and shield to hexon was 1:5 as previously
described43 with an MOI of 10 transducing units per cell (TU/cell).
Viral particle-containing supernatants were removed 3 h after infec-
tion and replaced by fresh culture medium. Luciferase activity was
determined by a luciferase assay (Promega, E1500) according to the
manufacturer’s instructions 72 h after infection.
In vivo biodistribution study (EMT6-HER2 model)
1  106 EMT6-HER2 cells, suspended in phenol red-free DMEM
(without supplements), were injected into the mammary gland of
8- to 12-week-old BALB/c WT mice. Once the tumors reached an
average volume of 40–60 mm3, luciferase-encoding retargeted and
shielded HCAdV or FG viruses (3 108 TU per mouse) were injected
intratumorally. The luciferase signal was determined in live animals
1 day after virus injection and 10 min after intraperitoneal injection
of 150 mg/kg D-luciferin (PerkinElmer) using the in vivo imaging sys-
tem NightOWL II LB 983 (Berthold Technologies). Following live
imaging, luciferase activity was determined in isolated tumors and or-
gans (draining and non-draining lymph node, spleen, liver, kidney,
lung, and heart). The overlay of the real image and the luminescence
representation allowed the localization and measurement of lumines-
cence emitted from xenografts. The signal intensities from manually
derived regions of interest (ROIs) were obtained and data were
expressed as photon flux (photons/s). All measurements were per-
formed under the same conditions, including camera settings, expo-
sure time (60 s), distance from lenses to the animals, and ROI size.
In vitro quantification of payload expression
For quantification of payload expression, A549 cells were infected
24 h after seeding (1  105 cells per well of a 24-well plate) at an
MOI of 10 TU/cell for single and triple payload-containing viruses.
A549 cells infected with a mixture of viruses were infected with the
same total MOI of 10 TU/cell, i.e., an MOI of 3.33 TU/cell per single
payload vector. Infected cells and cell supernatant were harvested 72 h
after infection. Infected cells were stored at 80C before mRNA
levels were quantified (see below). Cytokine secretion was determined
from supernatants using a mouse IL-12-p70 sandwich ELISA assay
(Invitrogen, 88-7121) for IL-12 and a mouse IL-2 sandwich ELISA
kit (Invitrogen, 88-7024) for IL-2, following the manufacturer’s in-
structions. RMP1-14 expression was quantified via an antigen capture
ELISA. A protein-binding 96-well plate (Thermo Fisher Scientific, 44-
2404-21) was coated with a 20 nMmurine PD-1 (Amsbio, AMS.PD1-
M82F4-25UG) solution at 4C overnight (100 mL/well). Following
blocking with 1 casein (Merck, B6429), the cell supernatant or a
standard of recombinantly produced and purified RMP1-14 anti-
bodies were applied. Following three wash steps with PBS + 0.1%
Tween 20, an alkaline phosphatase-coupled anti-mouse k-LC detec-
tion antibody (SouthernBiotech, 1050-04) was added. After wash,
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para-nitrophenylphosphate (p-NPP) was used as a substrate, and
absorbance at 406 nm was measured with an Infinite M1000 micro-
plate reader (Tecan). Antibody concentrations were determined
from a standard curve of recombinantly produced RMP1-14 protein
using a sigmoidal four parameter fit.
mRNA quantification by RT-PCR
To quantify mRNA levels of the expressed payloads by quantitative
reverse transcriptase PCR (qRT-PCR), RNA was extracted from cells
used for quantification of payload expression, according to the manu-
facturer’s instructions (Zymo Research, R1054). 500 ng of extracted
RNA was reverse-transcribed into cDNA using a QuantiTect reverse
transcription kit (QIAGEN, 205311) with the suppliedmix of oligo(dT)
and random primers. Following RT-PCR, cDNA samples were
analyzed by qPCR using specific primers for RMP1-14 (50-CGCTTC
TGTCGTGTGCTTCC-30, 50-TTGTGGGTAGCCTCGCATGT-30),
IL-12 (50-CCTGGCGAGACAGTGAACCT-30, 50-CCGCCCTTGTGA
CAGGTGTA-30), IL-2 (50-GCCACCGAGCTGAAGGATCT-30, 50-A
TGCTCTGGCAGAAGGCGAT-30), and GAPDH (50-AGCCACATC
GCTCAGACAC-30, 50-GCCCAATACGACCAAATCC-30) in single
reactions with a SYBR Green dye for quantification (Applied Bio-
systems, ANF00117457).
In vivo efficacy study (B16-HER2 model)
C57BL/6NWTmice were injected subcutaneously into the right flank
with 5 105 syngeneic B16-D5-HER2 cells suspended in phenol red-
free DMEM (without additives). Mice bearing palpable B16-HER2
tumors (average volume of 20–30 mm3) received intra-tumoral injec-
tion of 3  108 TU of HER2-targeted and shielded HCAdVs, coding
for the indicated payloads, on days 11, 13, 15, and 18 after tumor chal-
lenge. The tumor volume was calculated according to the formula:
V = 1/2[D (mm)  d
2 (mm)], with D and d being the longest and
shortest tumor diameter, respectively. Bodyweight and physiological
score, including appearance, behavior, and respiration, were moni-
tored during the whole experiment to detect signs of toxicity.
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